Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438   2/04/2026
3,515 CHF (-2,63%)
(-2,63%)   2/04/2026

30 maart 2026 · Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder · Persbericht

24 maart 2026 · Idorsia announces the nomination of three candidates for election to the Board of Directors · Persbericht

16 maart 2026 · Idorsia announces management change · Persbericht

10 maart 2026 · Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink · Persbericht

26 februari 2026 · Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026 · Persbericht

12 februari 2026 · Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call · Persbericht

6 februari 2026 · Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease · Persbericht

30 januari 2026 · Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium · Persbericht

28 januari 2026 · Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America · Persbericht

12 januari 2026 · Idorsia to present at J.P. Morgan 2026 Healthcare Conference · Persbericht

12 januari 2026 · Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease · Persbericht

6 januari 2026 · Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist · Persbericht

5 januari 2026 · Idorsia’s daridorexant in women during menopausal transition age with insomnia · Persbericht

5 januari 2026 · Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension · Persbericht

10 december 2025 · New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD · Persbericht

9 december 2025 · Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category · Persbericht

10 november 2025 · Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension · Persbericht

5 november 2025 · Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions · Persbericht

30 oktober 2025 · QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results · Persbericht

10 oktober 2025 · Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability · Persbericht

Mijn selecties